4D Molecular Therapeutics (FDMT) Operating Expenses (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Operating Expenses data on file, last reported at $76.7 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 42.94% year-over-year to $76.7 million in Q1 2026; TTM through Mar 2026 was $267.8 million, a 31.69% increase from a year earlier, with the FY2025 full-year figure at $244.8 million, up 30.27% from the prior year.
• Operating Expenses for Q1 2026 stood at $76.7 million, up from $70.4 million in the prior quarter.
• Over the last five years, Operating Expenses for FDMT reached as high as $76.7 million in Q1 2026 and fell as low as $27.0 million in Q3 2022.
• Historically, Operating Expenses has averaged $44.5 million across 5 years, with a median of $38.2 million in 2024.
• Across the five-year window, Operating Expenses grew 10.12% in 2023 and soared 53.19% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $30.0 million in 2022, then advanced by 22.24% to $36.6 million in 2023, then surged by 53.19% to $56.1 million in 2024, then grew by 25.41% to $70.4 million in 2025, then rose by 8.94% to $76.7 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $76.7 million in Q1 2026, $70.4 million in Q4 2025, and $61.3 million in Q3 2025.